Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

BTOG 2021 | Novel therapies on the horizon for lung cancer

Samreen Ahmed • 23 Apr 2021
BTOG 2021
Lung Cancer Non-Small Cell Lung Cancer Antibodies CAR-T

Samreen Ahmed, FRCP, MD, University Hospitals of Leicester, UK, discusses novel therapies for lung cancer such as those targeting KRAS mutations and antibody-drug conjugates for the treatment of HER2-driven non-small cell lung cancer. This interview took place during the 19th British Thoracic Oncology Group (BTOG) Annual Conference 2021.

More from Samreen Ahmed

3:29
Novel strategies to treating brain metastases in lung cancer
Samreen Ahmed • 27 Mar 2023
0:54
Early lung cancer at ELCC 2023
Samreen Ahmed • 27 Mar 2023
0:55
Management of brain metastases associated with lung cancer
Samreen Ahmed • 27 Mar 2023
3:06
Highlights from the BTOG 2023 therapeutics symposium
Samreen Ahmed • 26 Apr 2023

Related Videos

2:09
Is there a role for radiotherapy in extensive-stage SCLC?
Clive Peedell • 18 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
3:03
BTOG 2024 insights & future directions: a comprehensive approach to thoracic malignancies
Sanjay Popat • 19 Apr 2024
1:03
The benefits of liquid biopsies for lung cancer in the community setting
Deepti Behl • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals